Enstilar Approval History
- FDA approved: Yes (First approved October 16th, 2015)
- Brand name: Enstilar
- Generic name: betamethasone dipropionate and calcipotriene
- Dosage form: Foam
- Company: LEO Pharma Inc.
- Treatment for: Plaque Psoriasis
Enstilar (betamethasone dipropionate and calcipotriene) is a topical corticosteroid and vitamin D analogue foam formulation for the treatment of psoriasis vulgaris.
Development History and FDA Approval Process for Enstilar
|Oct 19, 2015||LEO Pharma Announces U.S. Approval of Enstilar Foam (calcipotriene/betamethasone dipropionate) for Plaque Psoriasis|
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.